BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7649072)

  • 1. [Major agitated-anxious versus blunted-retarded depression: differential effects of fluoxetine].
    Dalery J; Bouhassira M; Kress JP; Lancrenon S; Tafani A; Hantouche EG
    Encephale; 1995; 21(3):217-25. PubMed ID: 7649072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C; Ceccherininelli A; Rossi A; Maggini C
    Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients].
    Besançon G; Cousin R; Guitton B; Lavergne F
    Encephale; 1993; 19(4):341-5. PubMed ID: 8275922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
    Schöne W; Ludwig M
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():16-8. PubMed ID: 7959520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine in the treatment of anger: an open clinical trial.
    Rubey RN; Johnson MR; Emmanuel N; Lydiard RB
    J Clin Psychiatry; 1996 Sep; 57(9):398-401. PubMed ID: 9746447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study of the efficacy and acceptability of amineptine and fluoxetine in patients with major depression].
    Dalery J; Rochat C; Peyron E; Bernard G
    Encephale; 1992; 18(3):257-62. PubMed ID: 1299597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
    Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
    Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J; Aubin V
    Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of tianeptine in treating major recurrent unipolar depression. Study versus placebo for 16 1/2 months of treatment].
    Daléry J; Dagens-Lafant V; De Bodinat C
    Encephale; 1997; 23(1):56-64. PubMed ID: 9172969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.
    Rabkin JG; Rabkin R; Wagner G
    J Clin Psychiatry; 1994 Mar; 55(3):92-7. PubMed ID: 7915270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine treatment of dysthymia in the elderly.
    Nobler MS; Devanand DP; Kim MK; Fitzsimons LM; Singer TM; Turret N; Sackeim HA; Roose SP
    J Clin Psychiatry; 1996 Jun; 57(6):254-6. PubMed ID: 8666563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of morning versus evening fluoxetine administration.
    Usher RW; Beasley CM; Bosomworth JC
    J Clin Psychiatry; 1991 Mar; 52(3):134-6. PubMed ID: 2005078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.